Jun 04, 2020 / 05:00PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Hey, everybody. Good afternoon. And welcome to a very exciting session here at the 2020 Jefferies Global Healthcare Conference. I know that you're really anticipating all of the great commentary out of Dan and Andy with us. I'm really happy to introduce the Chairman and CEO of Gilead, Dan O'Day, there on the right side; and then the Chief Financial Officer, Andy Dickinson, with the wonderful Golden Gate Bridge in the background.
Daniel P. O'Day - Gilead Sciences, Inc. - Chairman & CEO
Hi, Mike.
Questions and Answers:
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity AnalystLet me just start off by saying, Dan, it's great to see you guys, and Andy, everyone. Obviously, super proud and happy to see all of the developments, particularly with remdesivir this year. But I just wanted to take a step back for Dan and ask him sort of, we are in some crazy times. You obviously are still trying to manage a business